Dachaigh › Luchd-obrach › Cerevel Therapeutics, LLC
Cerevel Therapeutics, LLC: Tuarastalan H-1B agus taic bhìosa
Chuir Cerevel Therapeutics, LLC 7 iarrtasan cumha-obrach a-steach airson bhìosaichean H-1B agus bhìosaichean co-cheangailte ann am bliadhnaichean ionmhais 2023–2026; le teisteanas: 7. Tuarastal meadhanach a chaidh a thabhann: $139,000.
A bheil Cerevel Therapeutics, LLC a’ toirt taic do bhìosaichean H-1B?
Chuir Cerevel Therapeutics, LLC 7 iarrtasan cumha-obrach a-steach ann am bliadhnaichean ionmhais 2023–2026, an tè as ùire air a chur a-steach air 12 Iuch 2024. Is e LCA a’ chiad cheum ann an iarrtas H-1B, mar sin tha an neach-fastaidh air taic a thoirt do luchd-obrach H-1B no air ullachadh airson sin a dhèanamh; cha gharantaich e taic airson dreuchd shònraichte sam bith. Thoir sùil air liostaichean obrach an neach-fastaidh fhèin.
Tuarastalan a rèir tiotal obrach
| Tiotal dreuchd | LCAs | Tuarastal meadhanach |
|---|---|---|
| Principal Analyst, Clinical Programming | 2 | $139,500 |
| Principal Scientist, Formulation Development | 2 | $130,500 |
| Senior Director, Medical Affairs | 1 | $300,000 |
| Senior Manager, Clinical Pharmacology | 1 | $180,000 |
| Research Scientist, Formulation Development | 1 | $120,119 |
Iarrtasan a rèir bliadhna ionmhais
| Bliadhna mhaoine | LCAs | Tuarastal meadhanach |
|---|---|---|
| FY2023 | 4 | $159,500 |
| FY2024 | 3 | $130,000 |
Ìrean tuarastail làithreach
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Far a bheil na h-obraichean
Dreuchdan
- Chemists3
- Molecular and Cellular Biologists2
- Medical and Health Services Managers1
- Medical Scientists, Except Epidemiologists1
Iarrtasan as ùire
| Tiotal dreuchd | Tuarastal bunasach | Àite | Air a chur a-steach | Ceann-latha tòiseachaidh | Inbhe |
|---|---|---|---|---|---|
| Principal Scientist, Formulation Development | $130,000–$166,000 Ìre IV | Somerset, NJ | 12 Iuch 2024 | 29 Iuch 2024 | Dearbhaichte |
| Principal Analyst, Clinical Programming | $140,000–$163,000 Ìre III | Larenceville, NJ | 4 Ògmh 2024 | 17 Ògmh 2024 | Dearbhaichte |
| Research Scientist, Formulation Development | $120,119–$138,000 | Cambridge, MA | 24 Gibl 2024 | 1 Dàmh 2024 | Dearbhaichte |
| Senior Manager, Clinical Pharmacology | $180,000–$191,113 Ìre IV | Cambridge, MA | 28 Ògmh 2023 | 17 Iuch 2023 | Dearbhaichte |
| Principal Analyst, Clinical Programming | $139,000–$164,000 Ìre III | Cambridge, MA | 17 Màrt 2023 | 10 Gibl 2023 | Dearbhaichte |
| Principal Scientist, Formulation Development | $131,000–$168,000 Ìre III | Cambridge, MA | 26 Dùbh 2022 | 30 Faoi 2023 | Dearbhaichte |
| Senior Director, Medical Affairs | $300,000–$350,000 Ìre IV | Cambridge, MA | 30 Ògmh 2022 | 18 Iuch 2022 | Dearbhaichte, an uair sin air a tharraing air ais |
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).